Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):525–530. doi: 10.1038/bjc.1996.91

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.

S Sen 1, E Erba 1, M D'Incalci 1, F Bottero 1, S Canevari 1, A Tomassetti 1
PMCID: PMC2074460  PMID: 8595169

Abstract

Lometrexol (5,10-dideazatetrahydrofolic acid; DDATHF), is a specific inhibitor of glycinamideribonucleosyl (GAR) transformylase with anti-tumour activity in murine and human carcinomas. The cytotoxicity activity of DDATHF was evaluated in vitro in NIH/3T3 cells transfected with human alpha-folate-binding protein (FBP) complementary DNA to examine the role of the receptor. In FBP-transfected NIH/3T3 (FBP-tNIH/3T3) cells, which internalised about three times more 5-methyltetrahydrofolic acid than the mock-transfected cells, the cytotoxtic potential of DDATHF showed a clear increase. Subsequently, we analysed four ovarian carcinoma cell lines (OVCAR3, IGROV1, SKOV3, and SW626) expressing different amounts of FBP. Cells were conditioned to grow in medium depleted of folic acid then tested by MOv18 and folic acid binding. Only SKOV3 and SW626 cells grown in folic acid-depleted medium showed increased FBP expression, about 3- and 8-fold respectively. The cytotoxic potential of DDATHF was evaluated by a standard clonogenic assay. In a medium containing 2.27 microM folic acid the DDATHF IC50 values were 50 nm on OVCAR3, 500 nM on SW626 and 1000 nM on IGROV1. In folic acid-free medium IC50 values were 2 nM on OVCAR3 and Sw626 and 40 nM on IGROV1. Only on SKOV3 cells was DDATHF cytotoxicity the same regardless of the amount of folic acid in the medium (IC50 8 nM). Thus, DDATHF did not inhibit the growth of IGROV1 cells depleted of folic acid after stripping FBP with phosphatidylinositol-phospholipase C, even at a dose toxic for cells constitutively expressing FBP. Although FBP expression is certainly one of the parameters affecting drug toxicity, taken alone it is not a sufficiently reliable predictor of cancer cell sensitivity to DDATHF.

Full text

PDF
525

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antony A. C. The biological chemistry of folate receptors. Blood. 1992 Jun 1;79(11):2807–2820. [PubMed] [Google Scholar]
  2. Baldwin S. W., Tse A., Gossett L. S., Taylor E. C., Rosowsky A., Shih C., Moran R. G. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry. 1991 Feb 19;30(7):1997–2006. doi: 10.1021/bi00221a037. [DOI] [PubMed] [Google Scholar]
  3. Beardsley G. P., Moroson B. A., Taylor E. C., Moran R. G. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem. 1989 Jan 5;264(1):328–333. [PubMed] [Google Scholar]
  4. Bottero F., Tomassetti A., Canevari S., Miotti S., Ménard S., Colnaghi M. I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res. 1993 Dec 1;53(23):5791–5796. [PubMed] [Google Scholar]
  5. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  6. Bénard J., Da Silva J., De Blois M. C., Boyer P., Duvillard P., Chiric E., Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985 Oct;45(10):4970–4979. [PubMed] [Google Scholar]
  7. Erba E., Sen S., Lorico A., D'Incalci M. Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. Eur J Cancer. 1992;28(1):66–71. doi: 10.1016/0959-8049(92)90387-h. [DOI] [PubMed] [Google Scholar]
  8. Erba E., Sen S., Sessa C., Vikhanskaya F. L., D'Incalci M. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. Br J Cancer. 1994 Feb;69(2):205–211. doi: 10.1038/bjc.1994.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fogh J., Wright W. C., Loveless J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977 Feb;58(2):209–214. doi: 10.1093/jnci/58.2.209. [DOI] [PubMed] [Google Scholar]
  10. Hamilton T. C., Young R. C., McKoy W. M., Grotzinger K. R., Green J. A., Chu E. W., Whang-Peng J., Rogan A. M., Green W. R., Ozols R. F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983 Nov;43(11):5379–5389. [PubMed] [Google Scholar]
  11. Jansen G., Westerhof G. R., Kathmann I., Rijksen G., Schornagel J. H. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds. Cancer Chemother Pharmacol. 1991;28(2):115–117. doi: 10.1007/BF00689699. [DOI] [PubMed] [Google Scholar]
  12. Kamen B. A., Johnson C. A., Wang M. T., Anderson R. G. Regulation of the cytoplasmic accumulation of 5-methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. J Clin Invest. 1989 Nov;84(5):1379–1386. doi: 10.1172/JCI114310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miotti S., Alberti S., Facheris P., Mantovani L., Fornaro M., Stella M., Ménard S., Canevari S., Colnaghi M. I. Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cells. Int J Cancer. 1992 May 28;51(3):499–505. doi: 10.1002/ijc.2910510326. [DOI] [PubMed] [Google Scholar]
  14. Miotti S., Canevari S., Ménard S., Mezzanzanica D., Porro G., Pupa S. M., Regazzoni M., Tagliabue E., Colnaghi M. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987 Mar 15;39(3):297–303. doi: 10.1002/ijc.2910390306. [DOI] [PubMed] [Google Scholar]
  15. Moran R. G., Baldwin S. W., Taylor E. C., Shih C. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem. 1989 Dec 15;264(35):21047–21051. [PubMed] [Google Scholar]
  16. Pizzorno G., Cashmore A. R., Moroson B. A., Cross A. D., Smith A. K., Marling-Cason M., Kamen B. A., Beardsley G. P. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. J Biol Chem. 1993 Jan 15;268(2):1017–1023. [PubMed] [Google Scholar]
  17. Pizzorno G., Moroson B. A., Cashmore A. R., Russello O., Mayer J. R., Galivan J., Bunni M. A., Priest D. G., Beardsley G. P. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res. 1995 Feb 1;55(3):566–573. [PubMed] [Google Scholar]
  18. Pizzorno G., Sokoloski J. A., Cashmore A. R., Moroson B. A., Cross A. D., Beardsley G. P. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines. Mol Pharmacol. 1991 Jan;39(1):85–89. [PubMed] [Google Scholar]
  19. Ray M. S., Muggia F. M., Leichman C. G., Grunberg S. M., Nelson R. L., Dyke R. W., Moran R. G. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst. 1993 Jul 21;85(14):1154–1159. doi: 10.1093/jnci/85.14.1154. [DOI] [PubMed] [Google Scholar]
  20. Ross J. F., Chaudhuri P. K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994 May 1;73(9):2432–2443. doi: 10.1002/1097-0142(19940501)73:9<2432::aid-cncr2820730929>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  21. Sadasivan E., Cedeno M. M., Rothenberg S. P. Characterization of the gene encoding a folate-binding protein expressed in human placenta. Identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding protein. J Biol Chem. 1994 Feb 18;269(7):4725–4735. [PubMed] [Google Scholar]
  22. Taylor E. C., Hamby J. M., Shih C., Grindey G. B., Rinzel S. M., Beardsley G. P., Moran R. G. Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues. J Med Chem. 1989 Jul;32(7):1517–1522. doi: 10.1021/jm00127a019. [DOI] [PubMed] [Google Scholar]
  23. Westerhof G. R., Jansen G., van Emmerik N., Kathmann I., Rijksen G., Jackman A. L., Schornagel J. H. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res. 1991 Oct 15;51(20):5507–5513. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES